Isis Pharmaceuticals Given New $27.00 Price Target at Canaccord Genuity (ISIS)
Investment analysts at Canaccord Genuity increased their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $23.00 to $27.00 in a note issued to investors on Tuesday, Analyst Ratings Network reports. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s target price suggests a potential downside of 14.61% from the company’s current price.
A number of other analysts have also recently weighed in on ISIS. Analysts at Goldman Sachs Group Inc. initiated coverage on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note to investors on Wednesday, September 4th. They set a “neutral” rating and a $26.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Isis Pharmaceuticals (NASDAQ:ISIS) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, August 20th. They now have a $27.00 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Isis Pharmaceuticals (NASDAQ:ISIS) from $18.00 to $20.00 in a research note to investors on Wednesday, August 7th.
Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $29.20.
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) traded down 0.60% during mid-day trading on Tuesday, hitting $31.62. 1,913,566 shares of the company’s stock traded hands. Isis Pharmaceuticals has a one year low of $7.56 and a one year high of $34.31. The stock has a 50-day moving average of $27.43 and a 200-day moving average of $22.97. The company’s market cap is $3.646 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter last year, the company posted ($0.01) earnings per share. Isis Pharmaceuticals’s revenue was down 19.5% compared to the same quarter last year. Analysts expect that Isis Pharmaceuticals will post $-0.56 EPS for the current fiscal year.
In other Isis Pharmaceuticals news, SVP Patrick R. O’neil unloaded 2,500 shares of the stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $27.09, for a total value of $67,725.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.